Health TrialsbyHealthPanel

LA PrEP Impact and Cost-effectiveness (TEAMS)

ConditionHiv
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexMale
Age18+
SponsorInstitute of HIV Research and Innovation Foundation, Thailand

About this trial

This study will have three components:

1. Discrete choice experiments 2. Analysis of routine service data 3. Impact and cost-effectiveness analyses using results from 1 and 2

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Minimum age of 18 years

Individual assigned male at birth reporting sex with men in the past 12 months

Self-reported HIV-negative MSM and TGW who either report interest in PrEP use, current PrEP use, or past PrEP use

Permit audio recording during the interview and/or discussion.

Disqualifiers

Not willing to participate in the study

Trial design

Design model

Single group

Treatments tested in this trial

  • In-depth interviews (IDI)

    Other intervention

    In-depth interviews (IDI) 20 MSM,20 TGW, current, previous PrEP users will assess which attributes are relevant each population. Posters will be used to recruit for IDIs. Self-reported HIV-negative who either report interest in current or past PrEP use will be eligible to participate in IDI. IDI will be conducted by a study by in-person, on-line interviews.

  • Focus group discussion (FGD)

    Other intervention

    Focus group discussion (FGD) will discuss a interested information from IDIs. IDIs will be informed, invited to a FGD. FGD recruit 6-10 IDI. 10 random number will be generated using statistical if more 10 individuals show interest in participating in a FGD. If there are less than 6 accepted participants for a FGD, the backup list or new participant will be invited. Study will perform FGD by in-person, on-line conference. Data obtained during a process will be used to create a list of attributes for each population, their levels to include in the choice tasks, ensuring that a choices are plausible, exchangeable.

Treatment groups

10,720 Participants
are divided into 1 treatment group
Group A: (PHASE I) Attributes identificationExperimental treatment 2 interventions

Trial outcomes

Primary outcomes

1

The epidemiological impact of long-acting antiretrovirals for HIV prevention among Thai MSM and TGW at risk of HIV infection

Epidemiological impact analyses will compare a current scenario in which PrEP is only available as an oral formulation to a scenario in which long-acting PrEP is also available.

Time frame
12 months
2

The cost-effectiveness of long-acting antiretrovirals for HIV prevention among Thai MSM and TGW at risk of HIV infection

The cost-effectiveness analysis will be based on previous HIV transmission models published by the Erasmus Medical Centre

Time frame
12 months

Secondary outcomes

1

Proportion of MSM and TGW indicating uptake of PrEP in hypothetic scenarios, impact of sociodemographic and behavioral characteristics on projected uptake

The uptake of different PrEP modalities will be measured via a discrete choice experiment survey with clients in KP-led PrEP clinic

Time frame
18 months
2

Preferred PrEP modalities among Thai MSM and TGW, trade-off of different PrEP attributes

To quantify preference for long-acting antiretrovirals as PrEP in Thai MSM and TGW using discrete choice experiments

Time frame
18 months
3

Patterns of PrEP use

Patterns of PrEP use will analyze from the data such as discontinuation rates and restarts of oral PrEP in KP-led PrEP program

Time frame
18 months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Institute of HIV Research and Innovation Foundation, Thailand

Lead sponsor

Erasmus Medical Center

Collaborator

Source ClinicalTrials.gov
Apply now